



IRB Protocol #:	
Abbreviated Study Title:	
Number of participants enrolled:	
Date QA initiated:	
Date QA completed:	
Name of individual completing checklist:	

#### **SECTION 1**

#### **Study Protocol**

☐ Yes ☐ No ☐ N/A No study proced	dures began prior to IRB approval.
binder.	inal signed protocol is on file in the regulatory
☐ Yes ☐ No ☐ N/A Past versions of	f the protocol are on file in the regulatory binder.
I I I I I I I I I I I I I I I I I I I	the protocol were submitted to the IRB and ceived prior to implementation of any changes.
documentation	remature un-blinding, the appropriate was provided to the IRB and sponsor.
or is asked to w regulatory binde	either the study participant decides to withdraw ithdraw by the PI, there is documentation in the er and it was reported to the IRB and sponsor.
and regulations	with study protocols and procedures, and rules concerning research were reported to the IRB.
deviations were	reporting criteria and significant protocol reported to the IRB and FDA within 10 business ecoming aware, and the sponsor was notified as
for either signific regulatory binde	of the IRBs response and/or recommendation cant protocol deviations or SAEs are on file in er.
protocol deviation binder.	AEs (that meet reporting criteria) and significant ons are documented on file in the regulatory
	AEs and significant protocol deviations was RB, FDA and sponsor, as appropriate.
☐ Yes ☐ No ☐ N/A Non-significant of by sponsor.	deviations were reported to the IRB, if required
	that external adverse safety reports were IRB, if applicable.
device, the IRB	mergency use of an investigational drug or was notified within 5 working days.
☐ Yes ☐ No ☐ N/A In the case that reported to the I	the study was suspended, the suspension was RB.





#### Study Documents/Records

Informed Consent:							
	Yes		No		N/A		versions of the informed consent document were approved the IRB.
	Yes		No		N/A	Cui	rrent and all previous versions of the IRB approved informed
						cor	nsent are in the regulatory binder.
	Yes		No		N/A	Inc	onsistencies in the informed consent process were submitted
						to t	he IRB and documentation is on file in the regulatory binder.
Inves	stigator/	Staff	Records				
	Yes		No		N/A	For	m 1572 was completed and submitted to the FDA/sponsor
						pric	or to the start of the study.
	Yes		No	П	N/A	Ori	ginal copy of Form 1572 remains on file in the regulatory
						1,227,000,000	der.
	Yes .		No		N/A	Any	y changes in principal investigator/sub investigator/study staff
						wei	re submitted and approved by IRB and sponsor, and
						doc	cumentation is on file in the regulatory binder.
Please indicate for the persons listed on Form FDA 1572, whether the following forms are on file:					m FDA 1572, whether the following forms are on file:		
	Yes		No		N/A	Coi	mpleted Financial Disclosure Form is on file in the regulatory
						bin	der.
	Yes		No		N/A	An	original copy of the most recent signed and dated CV is on
						file	on in the regulatory binder.
	Yes .		No		N/A	An	original copy of the most recent medical license issued in
						Illin	ois is on file in the regulatory binder.
	Yes		No		N/A	An	original copy of CITI training and any other specialty training
						is o	n file in the regulatory binder.
Lab F	Records	3:					
□ Y	/es		No		N/A		Normal lab values are in the regulatory binder or a hard
							copy is on file for the duration of the study.
	/es		No		N/A		Current license of the lab director is in the regulatory binder
							or a hard copy is on file.
	/es		No		N/A		Current CV of lab director is in the regulatory binder or a
							hard copy is on file.
Please indicate whether the following lab certifications are on file:							
□ Y	/es	П	No		N/A		CLIA certification is in the regulatory binder or a hard copy
							is on file for all involved laboratories.
	/es		No		N/A		CAP certification is in the regulatory binder or a hard copy is
1							on file for all involved laboratories





General Records:

□ Yes	□ No	□ N/A	Investigative Brochure is signed and dated by the PI.
□ Yes	□ No	□ N/A	The original copy of the Investigative Brochure signature page remains on file in the regulatory binder, along with a note to file stating that the full Investigative Brochure is stored electronically.
☐ Yes	□ No	□ N/A	The delegation log is on file in the regulatory binder.
☐ Yes	□ No	□ N/A	Advertisements used for recruitment were approved by the IRB and documentation is on file in the regulatory binder.
□ Yes	□ No	□ N/A	Each continuing review was submitted and approved by the IRB; documentation is on file in the regulatory binder.
☐ Yes	□ No	□ N/A	Documentation of correspondence relative to the conduct of the protocol and/or important decisions regarding study conduct (such as notes to file) is on file in the regulatory binder.
☐ Yes	□ No	□ N/A	Closure to enrollment was submitted to the IRB as applicable, and is on file in the regulatory binder.
□ Yes	□ No	□ N/A	Permanent Closure report was submitted to the IRB after all study activity is completed and is on file in the regulatory binder.
□ Yes	□ No	□ N/A	DSMB reports, if applicable, are on file in the regulatory binder.
☐ Yes	□ No	□ N/A	DSMB reports were received from sponsor, submitted to the IRB and correspondence of the IRB's receipt of the DSMB report is on file in the regulatory binder.

### **Document Retention (at study closure)**

□ Yes	□ No	□ N/A	Investigator retains records for 2 years following the date the marketing application is approved, 2 years after investigation is permanently closed, or as directed by the study sponsor.
□ Yes	□ No	□ N/A	For IND studies, investigator retains records for 2 years following the date the marketing application is approved, 2 years after the investigation is permanently closed, or as directed by the study sponsor.
□ Yes	□ No	□ N/A	For IDE studies, investigator retains records for 2 years following the date of permanent closure, the date that the records are no longer required for a premarket approval application, completion of a product development protocol, or as directed by the study sponsor.





### IDE - Investigational Device Exemption

□ N/A		If study does not fall under the purview of needing an IDE application, please check N/A and proceed to the next section.				
□ Yes	□ No	□ N/A	The IDE application, all supporting documents, FDA reports, and annual reports are filed in the IDE binder.			
IND – Inves	stigational Nev	w Drug				
□ N/A	The same of the sa	es not fall unde	r the purview of needing an IND application, please check N/A ection.			
□ Yes	□ No	□ N/A	The IND application, all supporting documents, FDA reports			
			and annual reports are filed in the IND binder.			





IRB Protocol 7	<b>#</b> :			
Abbreviated S	Study Title:			
Number of pa	rticipants enro	lled:		
Date QA initia	ited:			
Date QA com	pleted:			
Name of indiv	idual completi	ng checklist:		
Section 2	1 b	220.000 %		
Please refer to	o the participa	nt binders or or	nline medical record to complete this section.	
Number of pa	rticipants enro	lled:		
		to be reviewe		
(= the square	root +1 of part	ticipants enrolle	ed)	
Participant ID	number			
Data Collection of Subjects				
□ Yes	□ No	□ N/A	Participants met initial inclusion/exclusion criteria.	
□ Yes	□ No	□ N/A	There is a completed eligibility checklist.	
☐ Yes	□ No	□ N/A	Participant eligibility was verified after screening and before any study procedures were initiated.	
☐ Yes	□ No	□ N/A	The eligibility checklist includes signature/initials and date	
│□ Yes	LI NO	LI IN/A	of the person obtaining the information.	
☐ Yes	□ No	□ N/A	For persons who did not meet eligibility, identifiable	
			information was destroyed or authorization was obtained	
14			to keep subject information.	
☐ Yes	□ No	□ N/A	Data collection is complete and accurate for each subject,	
		1	including appropriate signatures/initials and the date.	
☐ Yes	□ No	□ N/A	Source documentation is available to support data entry.	
☐ Yes	□ No	□ N/A	The case report forms contain dated signatures or initials.	
☐ Yes	□ No	□ N/A	In the case that any changes or cross-outs were made,	
			the original data is still legible and contains a	
			signature/initials and date of changes made.	
☐ Yes	□ No	□ N/A	In the case that there is missing data, any additional	
I	l	1	added information is noted by signature/initial and the	

date.



### **Informed Consent of Subjects**

	Yes		No		N/A	Informed consent was obtained prior to any study
				ģ.		procedures.
	Yes		No		N/A	The consent forms on file are the original signed and dated
			(1			version.
	Yes		No		N/A	Study participants received and signed the most current IRB
						approved informed consent document.
	Yes		No		N/A	The subject received a copy of the signed and dated
						consent form.
	Yes		No		N/A	Documentation that participants had opportunity to ask
						questions, withdraw, decline participation, and sufficient time
						to make a decision; (proof of documentation could be the
						note in EPIC).
	Yes		No		N/A	All yes/no or similar options on the consent form are
						completed/initialed.
	Yes		No		N/A	Consent forms are free of any handwritten
						changes/corrections.
	Yes		No		N/A	In the case that the IRB required subjects to be re-
	ì					consented, subjects were accurately re-consented with the
						most up-to-date consent document or consent addendum.
	Yes		No		N/A	For persons who cannot read, a witness signed the informed
						consent document and the documentation is on file in
						participant binder.
	Yes		No		N/A	If applicable, minors who gave assent also signed and dated
						written informed consent/assent document and
						documentation is on file in participant binder.
Check the following boxes to indicate whether the following signature requirements for informed consent						
were met:						
	Yes		No		N/A	Research participant signature.
	Yes		No		N/A	Signature of individual conducting the informed consent
	71 (400)	32.32		53.754		discussion.
	Yes		No		N/A	Witness signature.
	Yes		No		N/A	Signature of parent/legal guardian/LARs.